Moreover, 5 randomized clinical trials (RCTs) with cardiovascular outcomes have shown the cardiovascular and renal benefits of some drugs in the GLP1-RA class (liraglutide, semaglutide, albiglutide, dulaglutide, efpeglenatide) in subjects with T2D at high cardiovascular risk [55], which could also extend to subjects with prediabetes. The gene discussed is GLP1R; the disease is prediabetes syndrome.